Back to Journals » Patient Preference and Adherence » Volume 2

Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER

Authors Birnbaum M, Sharif Z

Published 22 December 2008 Volume 2008:2 Pages 233—240

DOI https://doi.org/10.2147/PPA.S3346

Review by Single anonymous peer review

Peer reviewer comments 4



Michael Birnbaum1, Zafar Sharif2

1St. Luke’s-Roosevelt Hospital Center, 1111 Amsterdam Ave, New York, NY, USA; 2Columbia University College of Physicians and Surgeons, New York, NY, USA

Abstract: Antipsychotic medications provide the foundation for treatment of acute exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence to prescribed antipsychotic regimens remains the most important driver of suboptimal clinical outcomes in this population. This paper reviews the magnitude of the problem of medication non-adherence in patients with schizophrenia and the various factors that contribute to nonadherence, with particular emphasis on factors related to antipsychotic medications. The profile of the latest atypical antipsychotic, paliperidone extended-release (ER) tablets, is then reviewed and the implications of its unique pharmacokinetic profile for adherence in this patient population are discussed.

Keywords: schizophrenia, adherence, paliperidone, pharmacokinetics

Creative Commons License © 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.